Cargando…
Drug extravasation with Enfortumab vedotin
INTRODUCTION: Enfortumab vedotin is an antibody drug conjugate approved for management of pretreated locally advanced or metastatic urothelial carcinoma, which is associated with a rare risk of drug extravasation and soft tissue reactions. CASE REPORT: We report two cases of EV extravasation with su...
Autores principales: | Grant, Christopher Ryan, de Kouchkovsky, Dimitri, Kalebasty, Arash Rezazadeh, Mar, Nataliya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612376/ https://www.ncbi.nlm.nih.gov/pubmed/37401244 http://dx.doi.org/10.1177/10781552231185505 |
Ejemplares similares
-
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021) -
Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020) -
Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
por: Homma, Takamasa, et al.
Publicado: (2023) -
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023) -
Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)